Intercept Pharmaceuticals, Inc.

Good day and thank you for standing by. Welcome to the second quarter 2021 intercept pharmaceuticals earnings call. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during that portion of the call, you will need to press star 1 on your telephone. If you require any further assistance, please press R0. I would now like to hand the conference over to your speaker, Lisa DeFrancesco, Senior Vice President, Investor Relations and Corporate Affairs.

Thank you.

Good morning and thank you for joining us on today's call. This morning, we issued a press release announcing our second quarter 2021 results and financial position, which is available on our website at www.interceptpharma.com. Before we begin our discussion, I'd like to note that during this call, we will be making forward-looking statements, including statements regarding our approved products and clinical development programs, certain regulatory matters, and our strategy, prospects, financial guidance, and future commercial and financial performance. Listeners are cautioned not to place under reliance on these forward-looking statements which speak only as of the date of this call, and we undertake no obligation to update such statements except as required by law. These forward-looking statements are based on estimates and assumptions that, although believed to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. Some, but not necessarily all, of the risk factors that could cause our actual results to differ materially from our historical results or those anticipated or predicted by our forward-looking statements are discussed in this morning's press release and in our periodic public filings with the SEC. Today's call will begin with prepared remarks from our President and CEO, Jerry Durso. And today you will hear from a number of new members of the Intercept leadership team, including Chief Commercial Officer, Linda Richardson, President of Research and Development and Chief Medical Officer, Dr. Michelle Berry, Chief Financial Officer, Andrew Sake, and Dr. Gail Cockwell, Senior Vice President of Safety and Pharmacovigilance, will also be available for Q&A. Please limit yourself to one question in order to allow time for all questions to be addressed. Let me now turn the call over to our CEO, Jerry Durso. Jerry?